Promising new drugs in MPN therapy

During the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub spoke to Pemmaraju, MD Anderson Cancer Center, Houston, US. We asked, what are some of the promising new drugs in MPN therapy?

Pemmaraju begins by outlining current therapies that are being successfully combined with Janus kinase inhibitors (JAKi) in the frontline treatment setting. These include navitoclax, pelabresib, and selinexor; each combined with the JAKi backbone therapy, ruxolitinib. He then discusses agents aimed at patients who experience suboptimal responses to initial JAKi therapy. Pemmaraju concludes by highlighting novel therapeutic approaches that move beyond the conventional JAKi approach. These include monoclonal antibodies, calreticulin mutant-specific targeting, and the discovery and targeting of novel signaling pathways.